Biondvax Pharmaceuticals Stock Return On Equity
| BVXVDelisted Stock | USD 1.35 0.03 2.17% |
BiondVax Pharmaceuticals fundamentals help investors to digest information that contributes to BiondVax Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of BiondVax Stock. The fundamental analysis module provides a way to measure BiondVax Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BiondVax Pharmaceuticals stock.
BiondVax |
BiondVax Pharmaceuticals Company Return On Equity Analysis
BiondVax Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current BiondVax Pharmaceuticals Return On Equity | -56.02 |
Most of BiondVax Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BiondVax Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, BiondVax Pharmaceuticals has a Return On Equity of -56.0153. This is 133.69% higher than that of the Pharmaceuticals sector and 53.63% higher than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
BiondVax Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BiondVax Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BiondVax Pharmaceuticals could also be used in its relative valuation, which is a method of valuing BiondVax Pharmaceuticals by comparing valuation metrics of similar companies.BiondVax Pharmaceuticals is currently under evaluation in return on equity category among its peers.
BiondVax Fundamentals
| Return On Equity | -56.02 | |||
| Return On Asset | -0.31 | |||
| Current Valuation | 21.94 M | |||
| Shares Outstanding | 3.65 M | |||
| Shares Owned By Insiders | 20.01 % | |||
| Shares Owned By Institutions | 10.69 % | |||
| Number Of Shares Shorted | 4.88 K | |||
| Price To Earning | (4.91) X | |||
| Price To Book | 7.48 X | |||
| EBITDA | (10.5 M) | |||
| Net Income | (5.8 M) | |||
| Cash And Equivalents | 14.55 M | |||
| Cash Per Share | 2.23 X | |||
| Total Debt | 21.54 M | |||
| Current Ratio | 1.71 X | |||
| Book Value Per Share | (1.96) X | |||
| Cash Flow From Operations | (7.26 M) | |||
| Short Ratio | 0.32 X | |||
| Earnings Per Share | (2.35) X | |||
| Target Price | 39.0 | |||
| Number Of Employees | 33 | |||
| Beta | 2.37 | |||
| Market Capitalization | 4.97 M | |||
| Total Asset | 27.07 M | |||
| Retained Earnings | (115.83 M) | |||
| Working Capital | 12.03 M | |||
| Current Asset | 36.93 M | |||
| Current Liabilities | 1.7 M | |||
| Z Score | -6.6 | |||
| Net Asset | 27.07 M |
About BiondVax Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BiondVax Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BiondVax Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BiondVax Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in BiondVax Stock
If you are still planning to invest in BiondVax Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BiondVax Pharmaceuticals' history and understand the potential risks before investing.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |